IOTA (Increasing Organ Transplant Access) Model

Analysis updated November 9, 2026

Strategic questions for your team

Given that IOTA participation is mandatory for all eligible hospitals within selected DSAs, have we modeled our institution's projected performance score across all three domains — Achievement (60 pts), Efficiency (20 pts), and Quality (20 pts) — to determine whether we are likely to land above 60 (upside payment), in the neutral zone of 41–59 (no payment), or at or below 40 (downside risk beginning PY2), and what is our estimated net financial exposure across all Medicare FFS and MA kidney transplants if we score at the low end?
What is our institution's transplant target for PY1 (calculated as our 3-year baseline mean of deceased plus living donor transplants trended by the national growth rate), and do we have the operational capacity — surgical volume, organ procurement relationships, staffing, and waitlist size — to reach at least 95% of that target (the minimum threshold for any Achievement domain points) or ideally 125%+ of target (the threshold for the maximum 60/60 Achievement points and the full $15,000 per-Medicare-transplant upside payment)?
What is our current organ offer acceptance rate ratio relative to national peers, and have we conducted a detailed audit of our organ offer filters to identify unjustified refusals, since the Efficiency domain (20 points) scores on both achievement ranking (80th percentile or above = 20 points; below 20th percentile = 0 points) and an improvement benchmark set at 120% of our third baseline year rate — and what is the realistic maximum point gain we can achieve through filter modifications alone?
Beginning PY2 (July 1, 2026), hospitals scoring 40 or below face downside risk payments to CMS calculated as $2,000 × (40 − Score) / 40 per Medicare FFS kidney transplant — for a high-volume center performing 300+ Medicare transplants annually, a score of 0 would generate a $2,000 × 300 = $600,000 gross liability — so what is our board-approved downside risk tolerance, what financial reserves or stop-loss arrangements are in place, and have we stress-tested our exposure under a worst-case scenario similar to the Financial Fact Sheet's Participant B, which scored 37/100 and owed $150 per Medicare transplant?
What investments in transplant coordinators, advanced practice providers, care coordination infrastructure, and post-transplant follow-up protocols are required to protect our Quality domain score (composite graft survival rate, 20 points), given that hospitals below the 10th national percentile receive only 10/20 points and those at or above the 80th percentile earn the full 20/20 — and what is our current national graft survival ranking based on SRTR data, and what is the ROI of a targeted post-transplant care investment relative to the upside payment improvement it could generate?
Have we identified and formalized partnerships with referring nephrologists, dialysis facilities, outpatient clinics, and OPOs in our DSA to build the referral pipeline and living donor identification infrastructure needed to increase transplant volume, since the Participant Readiness Roadmap explicitly calls for formalizing collaborator agreements, and since the Achievement domain — worth 60% of the total performance score — is directly dependent on absolute transplant volume relative to a participant-specific historical benchmark that resets each year with rolling 3-year baselines?
Are we prepared to meet the IOTA Model's mandatory transparency and patient engagement requirements — specifically, publicly posting waitlist selection criteria on our website by the end of PY1, conducting at least semi-annual organ offer filter reviews with every Medicare beneficiary on our waitlist, displaying model participation notices in all treatment facilities and on our public website, and providing written patient notifications — and have we assigned ownership of these compliance obligations to a specific operational leader with an accountability timeline before the July 1, 2025 start date?
Have we fully onboarded to the 4Innovation (4i) platform, executed our Data Sharing Agreement, and established internal workflows to operationalize the monthly CCLFs, quarterly Patient Attribution Lists, and annual Transplant Target reports that CMS will push through 4i — and do we have an analytics team capable of translating these data feeds into real-time performance dashboards that flag trajectory toward the 60-point upside threshold or the 40-point downside trigger before the preliminary performance assessment arrives 5–9 months after each performance year closes?
Have we assessed how IOTA model performance will interact with our existing Medicare Advantage contracts, since the upside risk payment of up to $15,000 per transplant applies to both Medicare FFS and MA kidney transplants (MS-DRGs 008, 019, 650, 651, 652), while the downside risk payment of up to $2,000 per transplant applies only to Medicare FFS — and do we understand the implications for our MA payer negotiations, case rate structures, and total cost of care calculations under any overlapping value-based agreements?
Given that the IOTA Model runs through June 30, 2031, with transplant targets that reset annually using rolling 3-year baselines, have we modeled the multi-year compounding effect of volume growth on future-year targets — recognizing that a high-performing year (e.g., 141% of target as in Appendix Example A) will raise the baseline for subsequent PYs, potentially making it harder to earn Achievement domain points in later years — and do we have a 6-year strategic plan that sequences volume investments, efficiency improvements, and quality initiatives to sustain scores above 60 throughout PY1–PY6 rather than optimizing for a single year?

Traps and concerns

High-Volume Centers Face Punishing Benchmark Trap
The Achievement Domain transplant target is calculated as the average of three baseline years (July 1, 2021–June 30, 2024 for PY1) trended forward by the national growth rate. As illustrated in the Financial Fact Sheet's Example B, a high-volume center that performed 330 transplants historically had a target so elevated that achieving only 75% of it (248 transplants) yielded just 10 out of 60 Achievement points, triggering a total score of 37/100 and a downside payment of $150 per Medicare FFS transplant. For a center performing even 200 Medicare FFS transplants annually, that equals $30,000 owed to CMS — purely because historical excellence set an unachievable baseline. Centers that surged volume during COVID recovery years (which fall squarely in the PY1 baseline window) are especially exposed. Strategic mitigation requires immediate baseline year auditing against OPTN/SRTR records before CMS finalizes annual transplant targets, delivered by the first day of each PY.
Organ Offer Acceptance Incentive Conflicts With Transplant Safety Standards
The Efficiency Domain (20 points) rewards hospitals for increasing their organ offer acceptance rate ratio relative to both national ranking and their own improvement benchmark. Centers in the 20th percentile or below score zero points on achievement scoring; those below their baseline rate score zero on improvement scoring. This creates direct pressure to accept marginal or high-risk kidneys — including expanded criteria donor (ECD) or donation after circulatory death (DCD) organs — that transplant physicians might otherwise appropriately decline. Accepting such organs to chase Efficiency points could suppress the Quality Domain score (also 20 points), which measures composite graft survival rate ranked nationally: centers below the 10th percentile receive only 10 of 20 Quality points. Critically, an organ acceptance decision that boosts Efficiency points but causes graft failure degrades the cumulative graft survival denominator across all PYs, since the Quality measure is a running composite. This cross-domain scoring tension creates liability exposure under UNOS/OPTN Program Criteria requirements and poses patient safety and medical staff credentialing risks that hospital CMOs must address through explicit clinical governance protocols separating financial incentive review from individual organ acceptance decisions.
Payment Reconciliation Lag Creates Multi-Year Cash Flow Exposure
CMS notifies participants of their preliminary performance assessment only 5–9 months after each PY closes. Participants then have 30 days to request a targeted review, after which CMS issues the final score and payment determination at least 30 days later. This means PY2 downside payments (beginning July 1, 2026) may not be finalized until as late as Q2 2028. For a center with a score of 26/100 (as in Appendix Example B), the formula yields $700 per Medicare FFS transplant owed to CMS; at 200 Medicare transplants, that is a $140,000 retroactive liability. CFOs must carry downside risk reserves across open PYs simultaneously — by PY3, up to two prior PYs may be in reconciliation simultaneously — without certainty of final amounts. Targeted review is limited to data quality errors or misapplication of methodology; it is not a broad appeals mechanism. Hospitals should implement internal shadow-scoring systems that replicate CMS's three-domain calculations quarterly to anticipate year-end positions and accrue appropriate liabilities on financial statements.
Mandatory Participation With No Opt-Out Mechanism
IOTA is a mandatory model under Section 1115A authority for all eligible kidney transplant hospitals (non-pediatric, ≥15 transplants annually across three baseline years) within the approximately 50% of DSAs CMS selected. At model launch on July 1, 2025, 103 hospitals were designated; 95 remained eligible at PY2 start (July 1, 2026), suggesting 8 hospitals were affected by eligibility changes mid-model. Hospitals cannot voluntarily exit, and the PY2 Final Rule (June 1, 2026) demonstrates CMS's willingness to revise model provisions after launch, adding two-sided risk retroactively effective July 1, 2026 — a structural change that hospitals operating under PY1 upside-only assumptions could not have fully priced into multi-year capital plans. Any hospital in a mandatory DSA that subsequently drops below 15 annual transplants due to staffing shortages, program suspension, or accreditation issues faces both regulatory compliance gaps and potential mid-model exclusion without financial settlement clarity. Legal counsel should review whether a mid-model UNOS program suspension creates force majeure relief or constitutes a breach of the Data Sharing Agreement signed through the 4i platform.
Data Sharing Agreement and 4i Platform Onboarding as Compliance Gate
IOTA participants must complete onboarding to the 4Innovation (4i) platform and execute a Data Sharing Agreement before accessing any CMS-provided data, including CCLFs (shared monthly), Patient Attribution Lists (quarterly, 15 days before PY start), and the annual Transplant Target report (provided by the first day of each PY). Failure to complete 4i onboarding before the PY start date means a hospital begins the performance period without its official transplant target, attribution list, or historical claims data — operating blind on the 60-point Achievement Domain. CMS shares attribution lists only 15 days before the PY begins, leaving minimal runway for clinical workflow alignment. Additionally, the standard provisions finalized in the 2024 Final Rule include cooperation requirements in model evaluation and monitoring, audit rights, record retention mandates, and intellectual property provisions for data generated during participation. Non-compliance with these provisions can trigger remedial action or model termination by CMS under the standard provisions framework. Hospitals must designate a primary IT/compliance lead specifically for 4i credential management and ensure CMS holds current primary contact name, email, and phone — the minimum required for receiving the platform invitation.
Publicly Posted Waitlist Criteria Face Accessibility and Equity Scrutiny Under IOTA
IOTA requires participants to publicly post their kidney transplant waitlist evaluation and selection criteria on their public-facing website by the end of PY1 (June 30, 2026). Additionally, they must review transplant organ offer acceptance criteria with each Medicare-attributed waitlist patient at least every 6 months. These dual transparency requirements create distinct legal hazards. First, a JAMA study published in October 2026 examining the accessibility of publicly posted waitlist criteria under IOTA found variation in how centers have implemented this requirement, raising concerns about whether posted criteria are practically accessible and equitable — amplifying external scrutiny by civil rights organizations, plaintiffs' attorneys, and CMS's Office for Civil Rights. This is particularly acute given that OPTN data cited in the IOTA NPRM acknowledges that organ transplantation 'remains highly inequitable amongst racial and ethnic minorities.' Any waitlist criteria that disproportionately screen out protected classes (e.g., BMI thresholds, compliance scoring, transportation-dependent requirements) now carries heightened disparate impact litigation risk once publicly posted. Second, the semi-annual patient review requirement for Medicare beneficiaries on the waitlist creates a documentation burden that transplant coordinators must operationalize at scale — a center with 200+ attributed Medicare waitlist patients must conduct and document approximately 400+ review touchpoints annually. Failure to meet this cadence constitutes a model compliance violation reviewable under the standard provisions audit framework. Centers should conduct a legal and plain-language accessibility review of all posted criteria before and after each update cycle.
Quality Domain Accumulates Failure Risk Across All PYs Simultaneously
The Quality Domain's composite graft survival rate is calculated as total functioning grafts divided by total transplants completed — not just within a single PY, but cumulatively. As explicitly illustrated in the Welcome Webinar slides, by PY2 a center's denominator includes all transplants from PY1 and PY2 combined, with graft failures from any prior PY reducing the numerator. This means a center that performs aggressively in PY1 to maximize Achievement Domain points (which carry 60 of 100 possible points) is building a large transplant cohort whose long-term graft survival will be tracked through PY6 (ending June 30, 2031). A single bad clinical year — a transplant-associated infection outbreak, a suboptimal organ acceptance policy driven by Efficiency Domain incentives, or a post-transplant immunosuppression management failure — permanently degrades the cumulative Quality score for all remaining PYs. Quality Domain scoring is based on national percentile ranking against both IOTA and non-IOTA hospitals; dropping below the 10th percentile yields only 10 of 20 Quality points. Centers with large transplant volumes that underperform on quality face a compounding disadvantage: more transplants mean more graft failures in absolute terms even at the same failure rate, while national ranking is indifferent to volume. CMOs should establish prospective graft survival dashboards updated at least quarterly against SRTR benchmarks to detect deteriorating trends before they crystallize into the annual CMS performance calculation.